These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 30027464)

  • 1. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
    Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
    Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
    Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
    PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
    Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H
    Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
    Fukushima T; Wakatsuki Y; Kobayashi T; Sonehara K; Tateishi K; Yamamoto M; Masubuchi T; Yoshiike F; Hirai K; Hachiya T; Koizumi T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1043-1050. PubMed ID: 29644460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
    Gautschi O; Mach N; Rothschild SI; Li Q; Stahel RA; Zippelius A; Cathomas R; Früh M; Betticher DC; Peters S; Rauch D; Feilchenfeldt J; Bubendorf L; Savic S; Jaggi R; Leibundgut EO; Largiadèr C; Brutsche M; Pilop C; Stalder L; Pless M; Ochsenbein AF;
    Clin Lung Cancer; 2015 Sep; 16(5):358-65. PubMed ID: 25843489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.
    Tamiya M; Tamiya A; Shiroyama T; Takeoka S; Naito Y; Omachi N; Kimura Y; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
    Invest New Drugs; 2018 Aug; 36(4):608-614. PubMed ID: 29101518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
    Takeoka H; Yamada K; Naito Y; Matsuo N; Ishii H; Tokito T; Azuma K; Ichiki M; Hoshino T
    Anticancer Res; 2018 Jun; 38(6):3779-3784. PubMed ID: 29848743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
    Li T; Piperdi B; Walsh WV; Kim M; Beckett LA; Gucalp R; Haigentz M; Bathini VG; Wen H; Zhou K; Pasquinelli PB; Gajavelli S; Sreedhara M; Xie X; Lara PN; Gandara DR; Perez-Soler R
    Clin Lung Cancer; 2017 Jan; 18(1):60-67. PubMed ID: 27919627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
    Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
    Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
    Tani T; Naoki K; Yasuda H; Arai D; Ishioka K; Ohgino K; Yoda S; Nakayama S; Satomi R; Terai H; Ikemura S; Sato T; Soejima K
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1065-1071. PubMed ID: 31493177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.
    Kimura T; Taniguchi H; Watanabe N; Saka H; Kogure Y; Shindo J; Ogasawara T; Kojima E; Hasegawa Y; Yamamoto M; Suzuki R; Ando M; Kondo M; Saito H
    Anticancer Res; 2016 Apr; 36(4):1767-71. PubMed ID: 27069157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
    Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
    Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
    Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
    Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
    Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
    Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer.
    Weiss JM; Villaruz LC; O'Brien J; Ivanova A; Lee C; Olson JG; Pollack G; Gorman R; Socinski MA; Stinchombe TE
    Clin Lung Cancer; 2016 Mar; 17(2):128-32. PubMed ID: 26774201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
    Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Michelsen L; Sørensen JB
    Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA;
    Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.